Simulation of the sedative effect of high doses of detomidine in equines
DOI:
https://doi.org/10.31533/pubvet.v12n11a218.1-5Keywords:
Pharmacokinetic/pharmacodynamic modeling, alpha 2 agonists, clinical pharmacologyAbstract
The objective of the study was to simulate the sedative effect of the administration of detomidine in doses of 80 ug/kg by intravenous and intramuscular route in equines. A pharmacokinetic/pharmacodynamic (PK/PD) model was performed with the sigmoid curve of plasma concentration, obtained by Mama and collaborators, depending on the effect on the head position by means of Hill equation. A sedative effect simulation of 80 ug/kg intravenous (IV) and intramuscular (IM) doses by Hill's equation was then performed. Higher and prolonged plasmatic concentrations were obtained after administrations of 80 ug/kg, when compared to administrations of 30 ug/kg resulting in higher and longer effect. The simulation of the effect of detomidine after administration of 80 ug/kg IV determined effects in the head height higher than 90%, 75% and 50% up to 2, 4 and 6 hours after administration. Meanwhile, the simulation of the effect of detomidine after the administration of 80 ug/kg IM determined effects in head height higher than 90%, 75% and 50% up to 3, 4 and 6 hours after administration. The present simulation showed that the effects of the position of the head after the administration of 80 ug/kg of detomidine via IV and IM in equines are superior and more prolonged when compared to the administration of 30 ug/kg. Therefore, in vivo studies should be performed in order to verify the adverse effects of these dosages in equines.
Downloads
Published
Issue
Section
License
Copyright (c) 2018 Lucas Valeiras Gaddini, Marilda Onghero Taffarel, Marcos Ferrante
This work is licensed under a Creative Commons Attribution 4.0 International License.
Você tem o direito de:
Compartilhar — copiar e redistribuir o material em qualquer suporte ou formato
Adaptar — remixar, transformar, e criar a partir do material para qualquer fim, mesmo que comercial.
O licenciante não pode revogar estes direitos desde que você respeite os termos da licença. De acordo com os termos seguintes:
Atribuição
— Você deve dar o crédito apropriado, prover um link para a licença e indicar se mudanças foram feitas. Você deve fazê-lo em qualquer circunstância razoável, mas de nenhuma maneira que sugira que o licenciante apoia você ou o seu uso. Sem restrições adicionais
— Você não pode aplicar termos jurídicos ou medidas de caráter tecnológico que restrinjam legalmente outros de fazerem algo que a licença permita.